ATE532521T1 - Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis - Google Patents

Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis

Info

Publication number: ATE532521T1
Authority: AT; Austria
Prior art keywords: estrogen; treatment; preparation; containing composition; atrophic vaginitis
Prior art date: 2000-12-15

Application number

AT01270333T

Other languages

English (en)

Inventor

Ingelise Kvorning

Karen Koch

Original Assignee

Novo Nordisk Femcare Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-15

Filing date

2001-12-13

Publication date

2011-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27222474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE532521(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-12-13 Application filed by Novo Nordisk Femcare Ag filed Critical Novo Nordisk Femcare Ag

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE532521T1 publication Critical patent/ATE532521T1/de

Links

239000000262 estrogen Substances 0.000 title abstract 4
229940011871 estrogen Drugs 0.000 title 2
208000004746 Atrophic Vaginitis Diseases 0.000 title 1
206010003693 Atrophic vulvovaginitis Diseases 0.000 title 1
201000010808 postmenopausal atrophic vaginitis Diseases 0.000 title 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
229960005309 estradiol Drugs 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000003442 weekly effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

AT01270333T 2000-12-15 2001-12-13 Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis ATE532521T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DKPA200001892		2000-12-15
DKPA200001890		2000-12-15
DKPA200001891		2000-12-15
PCT/DK2001/000824 WO2002047692A1 (en)	2000-12-15	2001-12-13	Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis

Publications (1)

Publication Number	Publication Date
ATE532521T1 true ATE532521T1 (de)	2011-11-15

Family

ID=27222474

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01270333T ATE532521T1 (de)	2000-12-15	2001-12-13	Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis

Country Status (10)

Country	Link
EP (3)	EP3747443A3 (de)
JP (2)	JP4851057B2 (de)
AT (1)	ATE532521T1 (de)
AU (1)	AU2002221567A1 (de)
CY (1)	CY1112542T1 (de)
DE (2)	DE10179223T1 (de)
DK (2)	DK1343508T3 (de)
ES (2)	ES2725774T1 (de)
PT (1)	PT1343508E (de)
WO (1)	WO2002047692A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3747443A3 (de)	2000-12-15	2021-03-03	Novo Nordisk Health Care AG	Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis
GT200500315A (es) *	2004-11-02	2006-06-06		Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
EP3272333A1 (de) *	2016-07-22	2018-01-24	Chemo Research, S.L.	Vaginale zubereitung enthaltend eine kombination von östrogen und vitamin d
EP3603626A1 (de)	2018-07-31	2020-02-05	Mucosa Innovations, S.L.	Zusammensetzung zur verwendung bei der vorbeugung und/oder behandlung von urogenitalmukosa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2739558B1 (fr) *	1995-10-05	1997-11-28	Innothera Lab Sa	Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
AU5181200A (en) *	1999-06-04	2000-12-28	General Hospital Corporation, The	Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
EP3747443A3 (de)	2000-12-15	2021-03-03	Novo Nordisk Health Care AG	Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis

2001
- 2001-12-13 EP EP20193530.1A patent/EP3747443A3/de not_active Withdrawn
- 2001-12-13 DK DK01270333.6T patent/DK1343508T3/da active
- 2001-12-13 ES ES10179223T patent/ES2725774T1/es active Pending
- 2001-12-13 AU AU2002221567A patent/AU2002221567A1/en not_active Abandoned
- 2001-12-13 DE DE10179223.2T patent/DE10179223T1/de active Pending
- 2001-12-13 DK DK10179223.2T patent/DK2366395T2/da unknown
- 2001-12-13 PT PT01270333T patent/PT1343508E/pt unknown
- 2001-12-13 WO PCT/DK2001/000824 patent/WO2002047692A1/en not_active Ceased
- 2001-12-13 EP EP10179223A patent/EP2366395A1/de not_active Ceased
- 2001-12-13 ES ES01270333T patent/ES2376649T3/es not_active Expired - Lifetime
- 2001-12-13 EP EP01270333A patent/EP1343508B1/de not_active Revoked
- 2001-12-13 JP JP2002549263A patent/JP4851057B2/ja not_active Expired - Fee Related
- 2001-12-13 AT AT01270333T patent/ATE532521T1/de active
- 2001-12-14 DE DE20120246U patent/DE20120246U1/de not_active Expired - Lifetime
2010
- 2010-04-08 JP JP2010089241A patent/JP2010189409A/ja active Pending
2012
- 2012-01-18 CY CY20121100064T patent/CY1112542T1/el unknown

Also Published As

Publication number	Publication date
EP1343508A1 (de)	2003-09-17
DK1343508T3 (da)	2012-02-27
EP2366395A1 (de)	2011-09-21
EP3747443A3 (de)	2021-03-03
ES2376649T3 (es)	2012-03-15
JP4851057B2 (ja)	2012-01-11
JP2004515531A (ja)	2004-05-27
CY1112542T1 (el)	2015-12-09
EP1343508B1 (de)	2011-11-09
DE10179223T1 (de)	2019-10-24
JP2010189409A (ja)	2010-09-02
EP3747443A2 (de)	2020-12-09
WO2002047692A1 (en)	2002-06-20
PT1343508E (pt)	2012-02-20
DK2366395T2 (da)	2020-06-15
DK2366395T1 (da)	2019-09-23
DE20120246U1 (de)	2002-05-29
AU2002221567A1 (en)	2002-06-24
ES2725774T1 (es)	2019-09-27

Publication	Publication Date	Title
WO2002094275A8 (en)	2003-02-13	Use of estrogen compounds to increase libido in women
ATE347365T1 (de)	2006-12-15	Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
ATE336239T1 (de)	2006-09-15	Neue fettsäureanaloge zur behandlung des bluthochdrucks
DK0928184T3 (da)	2009-09-28	Orale anti-karies sammensætninger
MXPA02010945A (es)	2004-07-16	Composiciones cosmeticas que contienen una silicona aminada y un agente espesante y sus utilizaciones.
DE60129550D1 (de)	2007-09-06	Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
DE69008476D1 (de)	1994-06-01	Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose.
MXPA06012500A (es)	2007-07-11	Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
ATE155007T1 (de)	1997-07-15	Parasitizide zusammensetzung und verfahren zu ihrer herstellung und ihre verwendung
ATE104542T1 (de)	1994-05-15	Hygienische zahnzusammensetzung zur verminderung periodontaler krankheiten.
CY1112542T1 (el)	2015-12-09	Χρηση ενος οιστρογονου για τη βιομηχανικη κατασκευη μιας συνθεσης που περιεχει οιστρογονο για τη θεραπεια ατροφικης κολπιτιδας
MY128392A (en)	2007-01-31	6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(2-FURANYLCARBOXYL)OXY]-11ß-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
ATE246515T1 (de)	2003-08-15	Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
BR9806893A (pt)	2000-05-16	Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 a 038 g/ml, compreendendo sulfato de terbutalina, processo para preparação da formulação e uso da mesma
GB2362103B (en)	2002-10-16	Pharmaceutical compositions including alginates
ATE352310T1 (de)	2007-02-15	Verwendung von zeoliten zur herstellung oraler zubereitungen zur behandlung von vergiftung
MXPA03010737A (es)	2004-03-02	Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
DE69501183D1 (de)	1998-01-22	Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
GB9814648D0 (en)	1998-09-02	Sub-lethal perfumes
ATE238750T1 (de)	2003-05-15	Kit zur konditionierung von zahnkavitäten
DE50107755D1 (en)	2006-03-02	3,3-dimethylcyclohexan-derivate
MXPA01002807A (es)	2004-03-19	Composiciones cosmeticas que contienen acetatos de alquilo superiores como emolientes.
IL154775A0 (en)	2003-10-31	21-hydroxy-6, 19-oxidoprogesterone (21oh-6, 19op) analogues, their preparation and use
OA09922A (en)	1994-09-15	Amalgam for filling cavities and method of preparation of compositions for the amalgam
ATE297737T1 (de)	2005-07-15	Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust